These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 3279997

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I.
    J Clin Oncol; 1995 Sep; 13(9):2354-60. PubMed ID: 7666094
    [Abstract] [Full Text] [Related]

  • 4. An update of two randomized trials in previously untreated multiple myeloma comparing melphalan and prednisone versus three- and five-drug combinations: an Argentine Group for the Treatment of Acute Leukemia Study.
    Pavlovsky S, Corrado C, Santarelli MT, Saslavsky J, Cavagnaro F, Palau M, de Tezanos Pinto M, Huberman A, Lein JM.
    J Clin Oncol; 1988 May; 6(5):769-75. PubMed ID: 3284974
    [Abstract] [Full Text] [Related]

  • 5. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM, Harrington DP, Abramson N, Kyle RA, Knospe W, Glick JH.
    Cancer; 1997 Apr 15; 79(8):1561-7. PubMed ID: 9118039
    [Abstract] [Full Text] [Related]

  • 6. Treatment of multiple myeloma: a randomized study of three different regimens.
    Tribalto M, Amadori S, Cantonetti M, Franchi A, Papa G, Pileri A, Boccadoro M, Dammacco F, Vacca A, Centurioni R.
    Leuk Res; 1985 Apr 15; 9(8):1043-9. PubMed ID: 3900591
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan 15; 124(2):212-22. PubMed ID: 8533996
    [Abstract] [Full Text] [Related]

  • 11. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF.
    J Clin Oncol; 2010 May 01; 28(13):2259-66. PubMed ID: 20368561
    [Abstract] [Full Text] [Related]

  • 12. Treatment of multiple myeloma.
    San Miguel JF, Bladé Creixenti J, García-Sanz R.
    Haematologica; 1999 Jan 01; 84(1):36-58. PubMed ID: 10091392
    [Abstract] [Full Text] [Related]

  • 13. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.
    Beksac M, Haznedar R, Firatli-Tuglular T, Ozdogu H, Aydogdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L.
    Eur J Haematol; 2011 Jan 01; 86(1):16-22. PubMed ID: 20942865
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
    Ahre A, Björkholm M, Mellstedt H, Brenning G, Engstedt L, Gahrton G, Gyllenhammar H, Holm G, Johansson B, Järnmark M.
    Cancer Treat Rep; 1984 Nov 01; 68(11):1331-8. PubMed ID: 6388832
    [Abstract] [Full Text] [Related]

  • 16. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
    Montuoro A, De Rosa L, De Blasio A, Pacilli L, Petti N, De Laurenzi A.
    Br J Haematol; 1990 Nov 01; 76(3):365-8. PubMed ID: 2261347
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S, Saslavsky J, Tezanos Pinto M, Palmer L, Curuchet M, Lein JM, Garay G, Dragosky M, Quiroga-Micheo E, Huberman AB.
    J Clin Oncol; 1984 Jul 01; 2(7):836-40. PubMed ID: 6376722
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.